332 related articles for article (PubMed ID: 18762220)
41. [Restriction analysis of Bordetella pertussis DNA isolated from patients with whooping cough in 1968 and 1995-98 and B. pertussis used for production of national vaccine strains].
Chodorowska M; Kuklińska D
Med Dosw Mikrobiol; 2000; 52(2):111-7. PubMed ID: 11107785
[TBL] [Abstract][Full Text] [Related]
42. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.
Schnoeller C; Roux X; Sawant D; Raze D; Olszewska W; Locht C; Openshaw PJ
Am J Respir Crit Care Med; 2014 Jan; 189(2):194-202. PubMed ID: 24261996
[TBL] [Abstract][Full Text] [Related]
43. Bordetella pertussis strain variation and evolution postvaccination.
Kallonen T; He Q
Expert Rev Vaccines; 2009 Jul; 8(7):863-75. PubMed ID: 19538113
[TBL] [Abstract][Full Text] [Related]
44. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
Cornford-Nairns R; Daggard G; Mukkur T
J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
[TBL] [Abstract][Full Text] [Related]
45. Engineering of an Iranian
Nikbin VS; Keramati M; Noofeli M; Tayebzadeh F; Kahali B; Shahcheraghi F
J Med Microbiol; 2020 Jan; 69(1):111-119. PubMed ID: 31778110
[No Abstract] [Full Text] [Related]
46. Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET.
Veal-Carr WL; Stibitz S
Mol Microbiol; 2005 Feb; 55(3):788-98. PubMed ID: 15661004
[TBL] [Abstract][Full Text] [Related]
47. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases.
Cauchi S; Locht C
Front Immunol; 2018; 9():2872. PubMed ID: 30581436
[No Abstract] [Full Text] [Related]
48. Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
Mallaley PP; Halperin SA; Morris A; MacMillan A; Lee SF
Can J Microbiol; 2006 May; 52(5):436-44. PubMed ID: 16699568
[TBL] [Abstract][Full Text] [Related]
49. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model.
David S; van Furth R; Mooi FR
Vaccine; 2004 May; 22(15-16):1892-8. PubMed ID: 15121300
[TBL] [Abstract][Full Text] [Related]
50. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
[TBL] [Abstract][Full Text] [Related]
51. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
52. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence?
Godfroid F; Denoël P; Poolman J
Expert Rev Vaccines; 2005 Oct; 4(5):757-78. PubMed ID: 16221076
[TBL] [Abstract][Full Text] [Related]
53. Protective activities of "Bordetella pertussis" Tn5 mutants in mice.
Olander RM; Muotiala A; Parviainen T; Runeberg-Nyman K
Ann Sclavo Collana Monogr; 1986; 3(1-2):329-35. PubMed ID: 2892513
[No Abstract] [Full Text] [Related]
54. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
[TBL] [Abstract][Full Text] [Related]
55. Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines.
Tatti KM; Slade B; Patel M; Messonnier N; Jackson T; Kirkland KB; Talbot EA; Tondella ML
Pediatr Infect Dis J; 2008 Jan; 27(1):73-4. PubMed ID: 18162945
[TBL] [Abstract][Full Text] [Related]
56. A new era of research into Bordetella pertussis pathogenesis.
Preston A; Maskell DJ
J Infect; 2002 Jan; 44(1):13-6. PubMed ID: 11972412
[No Abstract] [Full Text] [Related]
57. Vaccination with Bordetella pertussis-pulsed autologous or heterologous dendritic cells induces a mucosal antibody response in vivo and protects against infection.
George-Chandy A; Mielcarek N; Nordström I; Holmgren J; Eriksson K
Infect Immun; 2001 Jun; 69(6):4120-4. PubMed ID: 11349085
[TBL] [Abstract][Full Text] [Related]
58. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.
Lin A; Apostolovic D; Jahnmatz M; Liang F; Ols S; Tecleab T; Wu C; van Hage M; Solovay K; Rubin K; Locht C; Thorstensson R; Thalen M; Loré K
J Clin Invest; 2020 May; 130(5):2332-2346. PubMed ID: 31945015
[TBL] [Abstract][Full Text] [Related]
59. Comparative analysis of a Bordetella pertussis patient isolated strain and classical strains used in the pertussis vaccine.
Pereira A; Pereira AS; Moreira-Filho CA; Bando SY; Tambourgi DV
Vaccine; 2005 Jul; 23(34):4353-8. PubMed ID: 16005744
[TBL] [Abstract][Full Text] [Related]
60. Live pertussis vaccines: will they protect against carriage and spread of pertussis?
Locht C
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S96-S102. PubMed ID: 28341014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
